Table of Contents Table of Contents
Previous Page  12 / 23 Next Page
Information
Show Menu
Previous Page 12 / 23 Next Page
Page Background

Fase III inmuno-inmunoterapia

Pembrolizumab

Nivolumab

T-VEC

Epacadostat

Indoximod

BMS 986205

Inhibidores IDO